The US Food and Drug Administration (FDA) has approved medical technology company Zynex’s next-generation neuromuscular electrical stimulation (NMES) device, the M-Wave. This device is intended ...

Key Insights The projected fair value for Zynex is US$10.75 based on 2 Stage Free Cash Flow to Equity Zynex is... Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative ...

ENGLEWOOD, Colo. - Zynex , Inc. (NASDAQ: NASDAQ:ZYXI), a medical technology company known for noninvasive medical devices with a market capitalization of $255 million and impressive 79.7% gross ...

Zynex (ZYXI) has completed its clinical verification trial for their NiCO pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University. Trial completion is a key milestone ...

Zynex has completed the clinical verification trial of its pulse oximeter, NiCO, marking a significant milestone towards the Food and Drug Administration (FDA) clearance. Overseen by Duke ...

On Thursday, H.C. Wainwright maintained a positive stance on shares of Zynex Inc. (NASDAQ:ZYXI), reiterating a Buy rating and a $17.00 price target for the company's stock, representing ...

ENGLEWOOD, Colo., Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company ...